OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

Top Growing Medical Universities in Latin America: 2026 Edition by BIGR

FDA Approved Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient Metastatic Prostate Cancer

ASCO 2026 Highlights by GI Cancers Alliance: What’s New in Stomach Cancer Care

Christopher Jackson: Māori Die 7-8 Years Younger Than Non-Māori

Reirradiation in Gynecologic Cancer With Brachytherapy

When Online Identity Becomes Unclear: Why the Oncology Community Should Be Careful on X

Legend Biotech Highlights Early LB2501 Data at EHA 2026

Kristen Dahlgren: My Life Insurance Application Was Denied Due to My History of Cancer

Calculators

CTCAE v6.0 Adverse Events Grader

Grade adverse events based on CTCAE v6.0 criteria. Select an adverse event and enter the lab value or clinical finding to determine the severity grade (1-5).

Enter the lab value or clinical finding

CTCAE v6.0 Grade Scale:

  • Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
  • Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL.
  • Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated.
  • Grade 4: Life-threatening consequences; urgent intervention indicated.
  • Grade 5: Death related to AE.